Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Paysign Q4 2025 Earnings Call - Patient affordability scales, driving a clear margin inflection
Paysign closed 2025 with a classic growth-with-leverage story. Revenue rose 40.5% to $82.0 million, driven by a 168% surge in patient affordability revenue to $33.9 million and a steady plasma busines...
- 2025 results show scale and leverage: revenue +40.5% to $82.0 million, net income +98% to $7.6 million, adjusted EBITDA +107% to $19.9 million.
- Operating margin inflection: operating margin rose 723 basis points to 9.0% in 2025, reflecting improved gross margin (59.4% vs 55.1%) and disciplined OpEx growth.
- Patient affordability is the growth engine: pharma revenue grew 167.8% to $33.9 million, driven by 55 net program additions to 131 active programs and ~79% growth in claims processed.
- +12 more takeaways
Blaize Holdings, Inc. Q4 2025 Earnings Call - Rapid Q4 Revenue Ramp and Services Pivot Amid Large Noncash Losses
Blaize ended 2025 with a sharp revenue acceleration, from roughly $1 million in Q1 to $23.8 million in Q4, producing $38.6 million for the full year and beating guidance. Management is positioning the...
- Revenue ramped sharply in 2025, from about $1 million in Q1 to $23.8 million in Q4, producing $38.6 million for the full year and exceeding guidance.
- Company issued 2026 revenue guidance of $130 million, unchanged from prior guidance, with the first half expected to be lighter than the second.
- Blaize plans to launch the Blaize AI Services platform in Q2 2026 to unify hardware, software, and API-based services and shift monetization toward inference transactions and services.
- +12 more takeaways
Spectral AI Q4 2025 Earnings Call - BARDA $31.7M Boost as FDA De Novo Decision Looms, Commercial rollout pushed into 2026
Spectral AI closed 2025 with a substantive BARDA funding boost and a thicker cash cushion, while the company waits on a pivotal FDA De Novo decision that will determine whether DeepView moves from tri...
- Company submitted De Novo application to the FDA in June 2025, received an additional information request, and states it has timely replied, with management hopeful for a positive FDA response before the end of Q2 2026.
- Completed a 15-month burn validation study in March 2025 covering 164 adult and pediatric patients across 15 U.S. burn centers and EDs; Spectral says DeepView significantly outperformed clinical judgment and those results were included in the De Novo submission.
- BARDA remains a long-term partner; Project BioShield contract is worth up to $150 million, with $55 million previously awarded and an additional $31.7 million of advanced funding just granted.
- +12 more takeaways
Comstock Inc Full Year 2025 Earnings Call - Nevada Recycling Plant Nears Commissioning as Big Asset Monetizations Get Real
Comstock says 2025 was a transformation year. With an oversubscribed equity raise, a cleaned-up balance sheet and first-of-kind Nevada permits in hand, the company is moving from pilot to industrial s...
- Comstock closed an oversubscribed equity offering in January 2026, raising $57.5 million gross and about $53 million net, broadening its institutional shareholder base including Hood River, Gratia and MAK Capital.
- Liquidity snapshot: cash and cash equivalents were approximately $56 million at March 20, 2026, and common shares outstanding are about 74 million.
- 2025 metals revenue was modest: Comstock Metals reported roughly $1.4 million revenue in 2025 versus $4.4 million in 2024, plus about $2.2 million of additional billings treated as deferred revenue, which together approximate the $3.5 million guidance.
- +13 more takeaways
Absci Corporation Q4 2025 Earnings Call - ABS-201 in clinic with favorable safety, 13-week AGA proof-of-concept due H2 2026
Absci used the quarter to pivot from platform proof to a clinical push. ABS-201, a prolactin receptor blocking antibody engineered for extended half-life, has entered the clinic and the company has do...
- ABS-201 is in the clinic, with the company having dosed the first three SAD cohorts in the phase I/IIa HEADLINE trial and planning to dose SAD Cohort 4 and the first MAD cohort next.
- Emerging safety data are described as favorable, with no mechanism-related or off-target safety signals observed so far, though management cautioned the dataset is still small.
- Preliminary safety, tolerability, and PK readouts for HEADLINE are expected in the first half of 2026, a 13-week interim proof-of-concept (PoC) for AGA is planned for H2 2026, and full 26-week PoC data are expected in early 2027.
- +15 more takeaways
Braze Fiscal Q4 2026 Earnings Call - AI Product Launches and Enterprise Momentum Re-accelerate Growth
Braze closed fiscal Q4 2026 with clear acceleration: revenue of $205.2 million, up 28% year over year, stronger bookings, and swelling enterprise traction that lifted ARR past $800 million and remaini...
- Q4 revenue $205.2 million, up 28% year over year and 8% sequentially; organic revenue growth for the quarter implied at 24.3% after Decisioning Studio contribution.
- Braze passed $800 million in ARR early in fiscal 2027 and reported over $1 billion in remaining performance obligations, signaling larger, longer customer commitments.
- Trailing 12-month dollar-based net retention inflected to 109%, a third straight quarter of year-over-year acceleration and a positive signal for upsell health.
- +13 more takeaways
AAR Corp Third Quarter FY2026 Earnings Call - Aftermarket Momentum Masks Near-Term Integration Drag
AAR reported a clean beat on growth and cash flow, driven by outsized strength in parts distribution, steady government demand, and accelerating Trax software adoption. Revenue was up 25% year over ye...
- Total sales grew 25% year over year to $845 million, with adjusted EBITDA up 26% to $102.1 million and adjusted diluted EPS up 26% to $1.25 per share.
- Organic adjusted sales growth was 14% for the quarter, led by 36% organic growth in new parts distribution.
- New parts distribution grew 62% in total, with roughly two thirds of that growth coming from same-store expansion and the remaining third from new contract wins.
- +12 more takeaways
TELA Bio Q4 2025 Earnings Call - Commercial overhaul keeps momentum, but company paces 2026 guidance amid execution risks
TELA Bio closed 2025 with 16% full year revenue growth to $80.3 million and a record Q4 at $20.9 million, powered by strong unit growth, European traction, and early adoption of LIQUIFIX. Management c...
- Revenue and profitability snapshot: Q4 2025 revenue $20.9 million, up 18% year over year; full year 2025 revenue $80.3 million, up 16% year over year.
- Unit growth outpaced revenue growth: OviTex unit sales grew 20% in Q4 and 22% for the year, while PRS unit sales grew 12% in Q4 and for the year, indicating mix dilution is pressuring ASPs.
- Product mix shift: higher share of smaller IHR units and rising inguinal and LPR volume reduced ASPs, management expects continued unit-driven volume growth even as revenue mix normalizes.
- +12 more takeaways
MaxCyte Q4 2025 Earnings Call - $4M SPL Headwind Keeps 2026 Modest, DTx Launch and SeQure Integration Offer Recovery Path
MaxCyte closed 2025 with $33.0 million in revenue, an install base of 857 instruments, and a business reshaped by customer program rationalizations. Management says the shortfall is concentrated, not ...
- Total revenue for full year 2025 was $33.0 million, down 15% from $38.6 million in 2024.
- Core revenue for 2025 was $29.6 million, SPL program related revenue was $3.4 million.
- Q4 2025 revenue was $7.3 million, down 16% year over year; Q4 core revenue was $6.8 million, down 22%.
- +14 more takeaways
Fractyl Health Q4 2025 Earnings Call - Ablation Length Emerges as Key Driver, Pivotal Built to Win
Fractyl doubled down on a clear narrative: the clinical signal for Revita is real, but it depends on two controllable things, patient selection and ablation dose. New analyses from the REMAIN-1 midpoi...
- Post hoc analysis of the REMAIN-1 midpoint cohort reveals a clear, monotonic dose response between duodenal ablation length and post-GLP-1 weight maintenance.
- An ablation length threshold of roughly 16 centimeters or more is associated with the strongest clinical effect; company will use >=16 cm as the operating standard going forward.
- In the full REMAIN-1 pivotal cohort, mean and median ablation lengths exceeded 16 centimeters, and all pivotal investigators were trained to consistently achieve more than 14 centimeters of ablation.
- +12 more takeaways